Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM ESTCompany ParticipantsRuxandra Draghia-Akli - Executive VP ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Bullish option flow detected in Novavax (NVAX) with 20,909 calls trading, 5x expected, and implied vol increasing almost 9 points to 75.20%.

Novavax (NVAX) stock in focus as the company boosts 2025 revenue outlook after better than expected Q3 revenue driven by partnerships for COVID shot. Read more here.

Novavax raised its annual revenue forecast for the third time this year on Thursday, banking on milestone payments from vaccine supply and licensing deals such as with Japan's Takeda Pharmaceuticals.

Analysts expect Novavax to report an earnings per share (EPS) of $-0.96. Anticipation surrounds Novavax's announcement, with investors hoping to hear about both surpassing estimates and receiving ...

Wondering if Novavax is a hidden bargain or just another biotech roller coaster? You are not alone, and getting to the bottom of its real value is more important than ever. Despite plenty of buzz, ...

Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid to Sanofi in line with its CLA ...

Novavax (NVAX) officially handed over U.S. marketing rights for its COVID-19 vaccine, Nuvaxovid, to Sanofi. This milestone triggered a $25 million payment to Novavax and highlights progress in their ...

Investing.com -- Novavax, Inc. (NASDAQ:NVAX) reported third quarter revenue of $70 million, significantly exceeding analyst expectations of $44.87 million, while posting a wider-than-anticipated loss ...